Avizakimab, formerly known as BOS161721, represents a innovative medicinal approach to treating immune-mediated disorders. This antibody medication selectively targets IL-18 , a vital signaling molecule https://aishanrns205056.blognody.com/50943782/avizakimab-a-thorough-investigation-into-bos161721-s-potential